At ASCO, Oral Presentation from Intergroupe Francophone Du Myelome (IFM) of Phase III Study (IFM 2005 02) Evaluating Continuous REVLIMIDÂ® in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant